Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Schluckebier, Luciene; Garay, Osvaldo U.; Zukin, Mauro; Ferreira, Carlos G.
• Is Part Of: Lung cancer. Volume 89:Issue 3(2015:Sep.)
• Page Start: 274
• Page End: 279
• Publication Date: 2015-09
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.06.015
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Lung cancer with PS2 status is a common condition accounting around 40%.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Economic data is useful to complement data about safety and efficacy.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">This is the first economic analysis based on PS2 dedicated trial of NSCLC patients.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Carboplatin plus pemetrexed is cost-effective when compared with pemetrexed.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Dedicated PS2 clinical trials and economic evaluations should be encouraged.</p> </list-item> </list> </p> </sec> </abstract>